Literature DB >> 20308386

Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.

Anne Sandberg1, Klaus Skovbo Jensen, Pierre Baudoux, Françoise Van Bambeke, Paul M Tulkens, Niels Frimodt-Møller.   

Abstract

Antibiotic treatment of Staphylococcus aureus infections is often problematic due to the slow response and recurrences. The intracellular persistence of the staphylococci offers a plausible explanation for the treatment difficulties because of the impaired intracellular efficacies of the antibiotics. The intra- and extracellular time- and concentration-kill relationships were examined in vitro with THP-1 cells and in vivo by use of a mouse peritonitis model. The in vivo model was further used to estimate the most predictive pharmacokinetic/pharmacodynamic (PK/PD) indices (the ratio of the maximum concentration of drug in plasma/MIC, the ratio of the area under the concentration-time curve/MIC, or the cumulative percentage of a 24-h period that the free [f] drug concentration exceeded the MIC under steady-state pharmacokinetic conditions [fT(MIC)]) for dicloxacillin (DCX) intra- and extracellularly. In general, DCX was found to have similar intracellular activities, regardless of the model used. Both models showed (i) the relative maximal efficacy (1-log-unit reduction in the numbers of CFU) of DCX intracellularly and (ii) the equal relative potency of DCX intra- and extracellularly, with the MIC being a good indicator of the overall response in both situations. Discordant results, based on data obtained different times after dosing, were obtained from the two models when the extracellular activity of DCX was measured, in which the in vitro model showed a considerable reduction in the number of CFU from that in the original inoculum (3-log-unit decrease in the number of CFU after 24 h), whereas the extracellular CFU reduction achieved in vivo after 4 h did not exceed 1 log unit. Multiple dosing of DCX in vivo revealed increased extra- and intracellular efficacies (2.5 log and 2 log units of reduction in the numbers of CFU after 24 h, respectively), confirming that DCX is a highly active antistaphylococcal antibiotic. PK/PD analysis revealed that fT(MIC) is the index that is the most predictive of the outcome of infection both intra- and extracellularly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308386      PMCID: PMC2876366          DOI: 10.1128/AAC.01400-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

Review 1.  Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?

Authors:  J Ciampolini; K G Harding
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

Review 2.  Animal model pharmacokinetics and pharmacodynamics: a critical review.

Authors:  D Andes; W A Craig
Journal:  Int J Antimicrob Agents       Date:  2002-04       Impact factor: 5.283

3.  Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model.

Authors:  Stéphane Carryn; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2003-03-13       Impact factor: 5.790

4.  Intracellular Staphylococcus aureus. A mechanism for the indolence of osteomyelitis.

Authors:  J K Ellington; M Harris; L Webb; B Smith; T Smith; K Tan; M Hudson
Journal:  J Bone Joint Surg Br       Date:  2003-08

5.  agr expression precedes escape of internalized Staphylococcus aureus from the host endosome.

Authors:  S N Qazi; E Counil; J Morrissey; C E Rees; A Cockayne; K Winzer; W C Chan; P Williams; P J Hill
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases.

Authors:  Allan G Jensen; Carsten H Wachmann; Frank Espersen; Jens Scheibel; Peter Skinhøj; Niels Frimodt-Møller
Journal:  Arch Intern Med       Date:  2002-01-14

7.  Survival of Staphylococcus aureus inside neutrophils contributes to infection.

Authors:  H D Gresham; J H Lowrance; T E Caver; B S Wilson; A L Cheung; F P Lindberg
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

8.  Invasion of human keratinocytes by Staphylococcus aureus and intracellular bacterial persistence represent haemolysin-independent virulence mechanisms that are followed by features of necrotic and apoptotic keratinocyte cell death.

Authors:  M Mempel; C Schnopp; M Hojka; H Fesq; S Weidinger; M Schaller; H C Korting; J Ring; D Abeck
Journal:  Br J Dermatol       Date:  2002-06       Impact factor: 9.302

9.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.

Authors:  Stéphane Carryn; Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more
  12 in total

1.  In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams.

Authors:  Jeshina Janardhanan; Jayda E Meisel; Derong Ding; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 2.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

Review 3.  Distinguishing between resistance, tolerance and persistence to antibiotic treatment.

Authors:  Asher Brauner; Ofer Fridman; Orit Gefen; Nathalie Q Balaban
Journal:  Nat Rev Microbiol       Date:  2016-04       Impact factor: 60.633

Review 4.  Are bloodstream leukocytes Trojan Horses for the metastasis of Staphylococcus aureus?

Authors:  Guy E Thwaites; Vanya Gant
Journal:  Nat Rev Microbiol       Date:  2011-02-07       Impact factor: 60.633

5.  Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages.

Authors:  Frédéric Peyrusson; Deborah Butler; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

6.  Antibiotic selection of Escherichia coli sequence type 131 in a mouse intestinal colonization model.

Authors:  Frederik Boetius Hertz; Anders Løbner-Olesen; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

7.  Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.

Authors:  Tore Bjerregaard Stage; Magnus Graff; Susan Wong; Louise Ladebo Rasmussen; Flemming Nielsen; Anton Pottegård; Kim Brøsen; Deanna L Kroetz; S Cyrus Khojasteh; Per Damkier
Journal:  Br J Clin Pharmacol       Date:  2018-01-10       Impact factor: 4.335

8.  Uropathogenic Escherichia coli Shows Antibiotic Tolerance and Growth Heterogeneity in an In Vitro Model of Intracellular Infection.

Authors:  Françoise Van Bambeke; Marta Putrinš; Ivana Kerkez; Paul M Tulkens; Tanel Tenson
Journal:  Antimicrob Agents Chemother       Date:  2021-09-27       Impact factor: 5.191

9.  Increased intracellular activity of MP1102 and NZ2114 against Staphylococcus aureus in vitro and in vivo.

Authors:  Xiao Wang; Xiumin Wang; Da Teng; Ruoyu Mao; Ya Hao; Na Yang; Zhanzhan Li; Jianhua Wang
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

10.  Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.

Authors:  Wei Yu; Jinru Ji; Tingting Xiao; Chaoqun Ying; Jiaheng Fang; Ping Shen; Yonghong Xiao
Journal:  Drug Des Devel Ther       Date:  2017-06-28       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.